Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Apolipoprotein E (APOE) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Apolipoprotein E (APOE) Products under Development by Stage of Development | 7 | 1 |
| Apolipoprotein E (APOE) Products under Development by Therapy Area | 8 | 1 |
| Apolipoprotein E (APOE) Products under Development by Indication | 9 | 1 |
| Apolipoprotein E (APOE) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Apolipoprotein E (APOE) Products under Development by Companies | 12 | 2 |
| Apolipoprotein E (APOE) Products under Development by Universities/Institutes | 14 | 2 |
| Apolipoprotein E (APOE) Therapeutics Assessment | 16 | 6 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 2 |
| Assessment by Route of Administration | 19 | 1 |
| Assessment by Molecule Type | 20 | 2 |
| Apolipoprotein E (APOE) Companies Involved in Therapeutics Development | 22 | 1 |
| LipimetiX Development Inc | 22 | 1 |
| Apolipoprotein E (APOE) Drug Profiles | 23 | 8 |
| AEM-28 Drug Profile | 23 | 3 |
| AEM-2802 Drug Profile | 26 | 1 |
| AEM-2814 Drug Profile | 27 | 1 |
| Monoclonal Antibodies to Target ApoE for Alzheimer's Disease Drug Profile | 28 | 1 |
| Recombinant ApoE4 for Dyslipidemia Drug Profile | 29 | 1 |
| Small Molecules to Activate ApoE for Alzheimer's Disease Drug Profile | 30 | 1 |
| Apolipoprotein E (APOE) Featured News &Press Releases | 31 | 7 |
| Oct 14, 2015: Capstone Therapeutics Announces Allowance of U.S. Patent for Treatment of Diabetes With Apo E Mimetic Peptides | 31 | 1 |
| Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides | 31 | 1 |
| Dec 16, 2014: Capstone Therapeutics Announces Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker Efficacy Signals | 32 | 1 |
| Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals | 33 | 1 |
| Jun 11, 2014: Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in Refractory Hypercholesterolemic Subjects | 34 | 1 |
| Jun 05, 2014: ApoE Immunotherapy and Prions Advance in Alzheimer s Research | 35 | 1 |
| Apr 08, 2014: Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1 Human Clinical Trial in LDL/non-HDL Cholesterol Reduction | 35 | 1 |
| Nov 19, 2013: Capstone Therapeutics Announces a LipimetiX Development Presentation at the American Heart Association Scientific Sessions: Pre-Clinical Data Demonstrating Significant Post Treatment Benefit of AEM-28 on Established Atherosclerotic Lesions | 36 | 1 |
| Dec 06, 2012: Capstone Therapeutics's Partner LipimetiX Obtains Orphan Drug Designation For AEM-28 To Treat Homozygous Familial Hypercholesterolemia | 37 | 1 |
| Appendix | 38 | 2 |
| Methodology | 38 | 1 |
| Coverage | 38 | 1 |
| Secondary Research | 38 | 1 |
| Primary Research | 38 | 1 |
| Expert Panel Validation | 38 | 1 |
| Contact Us | 38 | 1 |
| Disclaimer | 39 | 1 |